• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Cervical cancer screening in Germany. Current status].

作者信息

Schneider V

机构信息

Pathologisches Labor, Burgunderstr. 1, 79104, Freiburg, Deutschland.

出版信息

Pathologe. 2012 Jul;33(4):286-92. doi: 10.1007/s00292-012-1579-7.

DOI:10.1007/s00292-012-1579-7
PMID:22684274
Abstract

Cervical cancer screening was introduced in Germany 40 years ago and the incidence of cancer of the cervix has subsequently decreased by close to 70%. The remaining incidence of 5,600 cases per year represents only 2.8% of all newly occurring cases of cancer in women and these cases occur mainly in patients who do not participate in regular screening. Thus, cervical cancer screening by cytological smears has been proven to be successful. The structure of the German cancer screening program is characterized by decentralized organization, exclusive involvement of medical specialists such as gynecologists and pathologists and strict quality assurance. The recruitment is 50% on a yearly basis and the cumulative participation over 3 years reaches 79%. Since 2008 all laboratories are required to report complete data sets to local quality control agencies.The Joint Federal Committee in charge of evaluating new technologies in Germany mandated an inquiry into the possible role of screening by human papillomavirus (HPV) testing. According to this report published by the Institute for Quality Assurance and Efficiency in Healthcare there are indications for advantages. There are, however, no data in the literature as to possible disadvantages of HPV testing. A similar study for the US Preventive Services Task Force was published in May 2011 with almost identical conclusions.

摘要

相似文献

1
[Cervical cancer screening in Germany. Current status].
Pathologe. 2012 Jul;33(4):286-92. doi: 10.1007/s00292-012-1579-7.
2
[Cervical cancer screening: past--present--future].[宫颈癌筛查:过去——现在——未来]
Pathologe. 2009 Dec;30 Suppl 2:128-35. doi: 10.1007/s00292-009-1189-1.
3
[Cervical cancer in Mecklenburg-Western Pomerania. Tumor stage, histological tumor type, age and screening participation of 985 patients].[梅克伦堡-前波美拉尼亚州的宫颈癌。985例患者的肿瘤分期、组织学肿瘤类型、年龄及筛查参与情况]
Pathologe. 2016 Feb;37(1):78-83. doi: 10.1007/s00292-015-0120-1.
4
Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany.德国沃尔夫斯堡 HPV 初筛试点项目(WOLPHSCREEN)降低宫颈癌发病率。
Br J Cancer. 2019 May;120(10):1015-1022. doi: 10.1038/s41416-019-0453-2. Epub 2019 Apr 16.
5
[Screening for cervical and breast cancer].[宫颈癌和乳腺癌筛查]
Pathologe. 2016 Sep;37(5):477-89. doi: 10.1007/s00292-016-0228-y.
6
High risk HPV infection prevalence and associated cofactors: a population-based study in female ISSSTE beneficiaries attending the HPV screening and early detection of cervical cancer program.高危型 HPV 感染的流行情况及其相关影响因素:一项基于人群的研究,对象为参加 HPV 筛查和宫颈癌早期检测项目的 ISSSTE 受益女性。
BMC Cancer. 2019 Dec 10;19(1):1205. doi: 10.1186/s12885-019-6388-4.
7
Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.HPV 和细胞学检测在宫颈癌筛查中的相对性能。
J Natl Cancer Inst. 2018 May 1;110(5):501-508. doi: 10.1093/jnci/djx225.
8
Bethesda 2014 Implementation and Human Papillomavirus Primary Screening: Practices of Laboratories Participating in the College of American Pathologists PAP Education Program.贝塞斯达 2014 实施与人类乳头瘤病毒初筛:参与美国病理学家学院 PAP 教育计划的实验室的实践。
Arch Pathol Lab Med. 2019 Oct;143(10):1196-1202. doi: 10.5858/arpa.2018-0603-CP. Epub 2019 Apr 25.
9
Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.在未接种 HPV 疫苗且 HPV 阴性的老年女性中,最后一次筛查的年龄与宫颈癌剩余终生风险:一项建模研究。
Lancet Oncol. 2018 Dec;19(12):1569-1578. doi: 10.1016/S1470-2045(18)30536-9. Epub 2018 Nov 1.
10
Ensuring quality in cervical screening programmes based on molecular human papillomavirus testing.基于分子人乳头瘤病毒检测的宫颈癌筛查项目的质量保障
Cytopathology. 2019 May;30(3):273-280. doi: 10.1111/cyt.12679. Epub 2019 Feb 18.

引用本文的文献

1
Impact of HPV Testing Based on the 2020 Update of the German Cervical Cancer Screening Program-Data from a Retrospective Monocentric Study.基于2020年德国宫颈癌筛查计划更新的HPV检测影响——一项回顾性单中心研究的数据
Cancers (Basel). 2025 Jun 17;17(12):2024. doi: 10.3390/cancers17122024.
2
Two Years of Cytology and HPV Co-Testing in Germany: Initial Experience.德国两年的细胞学和人乳头瘤病毒联合检测:初步经验
Geburtshilfe Frauenheilkd. 2022 Aug 16;82(12):1378-1386. doi: 10.1055/a-1886-3311. eCollection 2022 Dec.
3
Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing.

本文引用的文献

1
[HPV-induced diseases of the female genital tract].[人乳头瘤病毒引起的女性生殖道疾病]
Pathologe. 2011 Nov;32(6):449-50. doi: 10.1007/s00292-011-1473-8.
2
Persistent carcinoma in cervical cancer screening: non-participation is the most significant cause.宫颈癌筛查中的持续性癌:未参与是最主要原因。
Acta Cytol. 2011;55(5):433-7. doi: 10.1159/000331811. Epub 2011 Oct 8.
3
Screening for the prevention of cervical cancer in the era of human papillomavirus vaccination: an Australian perspective.人乳头瘤病毒疫苗接种时代宫颈癌预防筛查:澳大利亚视角
欧洲的宫颈癌筛查项目:向 HPV 疫苗接种和基于人群的 HPV 检测的转变。
Viruses. 2018 Dec 19;10(12):729. doi: 10.3390/v10120729.
4
Cytology use for cervical cancer screening in Portugal: results from the 2005/2006 National Health Survey.葡萄牙宫颈癌筛查中的细胞学应用:2005/2006年全国健康调查结果
Eur J Public Health. 2014 Apr;24(2):253-8. doi: 10.1093/eurpub/ckt077. Epub 2013 Jun 20.
5
[Where is gynecological cytology in Germany going from here?].
Pathologe. 2012 Nov;33(6):477-8. doi: 10.1007/s00292-012-1699-0.
Acta Cytol. 2011;55(4):307-12. doi: 10.1159/000326956. Epub 2011 Jul 22.
4
Description of the national situation of cervical cancer screening in the member states of the European Union.欧盟成员国宫颈癌筛查国情描述。
Eur J Cancer. 2009 Oct;45(15):2685-708. doi: 10.1016/j.ejca.2009.07.017. Epub 2009 Sep 8.
5
Cervical cancer screening policies and coverage in Europe.欧洲的宫颈癌筛查政策与覆盖率
Eur J Cancer. 2009 Oct;45(15):2649-58. doi: 10.1016/j.ejca.2009.07.020. Epub 2009 Aug 19.
6
Test group biases and ethical concerns mar New England Journal of Medicine articles promoting HPV screening for cervical cancer in rural India.测试组偏差和伦理问题影响了《新英格兰医学杂志》中关于在印度农村推广宫颈癌人乳头瘤病毒筛查的文章。
Cytojournal. 2009 Jul 16;6:12. doi: 10.4103/1742-6413.53466.
7
How to evaluate emerging technologies in cervical cancer screening?如何评估宫颈癌筛查中的新兴技术?
Int J Cancer. 2009 Dec 1;125(11):2489-96. doi: 10.1002/ijc.24774.
8
Routine audit of large-scale cervical cancer screening programs.大规模宫颈癌筛查项目的常规审计
J Natl Cancer Inst. 2008 May 7;100(9):605-6. doi: 10.1093/jnci/djn131. Epub 2008 Apr 29.
9
Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands.在荷兰,未就诊仍是子宫颈癌筛查有效性的主要限制因素。
Int J Cancer. 2006 Nov 15;119(10):2372-5. doi: 10.1002/ijc.22114.
10
The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany.德国宫颈癌筛查模型:德国宫颈癌筛查决策分析模型的开发与验证
Eur J Public Health. 2006 Apr;16(2):185-92. doi: 10.1093/eurpub/cki163. Epub 2006 Feb 9.